Humacyte Appoints Rick McElheny as Senior VP of Business Development to Accelerate Bioengineered Tissue Partnerships
核心洞察
Humacyte has appointed Rick McElheny (搜索) as Senior Vice President of Business Development to expand corporate collaborations and accelerate commercialization of its regenerative medicine pipeline.
McElheny brings over 15 years of experience in corporate development and alliance management, having led high-value transactions including the $660 million sale of Vidara Therapeutics (搜索).
The appointment comes as Humacyte advances its bioengineered tissue platform, including FDA-approved Symvess (搜索) and pipeline programs for coronary bypass surgery and Type 1 diabetes (搜索) treatment.
Humacyte, Inc. (Nasdaq: HUMA) has appointed Rick McElheny (搜索) as Senior Vice President of Business Development, positioning the commercial-stage biotechnology company to expand strategic partnerships as it advances its bioengineered tissue platform. The appointment comes at what CEO Laura Nilason (搜索) describes as "an exciting and transformative moment" for the Durham, North Carolina-based company.
Strategic Leadership Addition
McElheny brings more than 15 years of experience in corporate development and alliance management at biopharma companies, with a proven track record in licensing, strategic partnerships, and preclinical collaborations. His appointment is designed to accelerate the development and commercialization of Humacyte's broad regenerative medicine pipeline.
"Discussions with prospective corporate partners highlight the potential value that has been created in our broad bioengineering platform, including cardiovascular applications," said Nilason. "Rick's strong track record in corporate development, his deep experience across strategic partnerships, and his passion for advancing impactful therapies make him an exceptional addition to our leadership team."
Proven Track Record in High-Value Transactions
Prior to joining Humacyte, McElheny served as Senior Vice President, Corporate Development and Alliance Management at Clearside Biomedical (搜索), Inc. and as Founder and Vice President of Corporate Development at Vidara Therapeutics (搜索). His experience includes leading the $660 million sale of Vidara Therapeutics and over $250 million in out-licensing transactions at Clearside Biomedical. McElheny holds an MBA from the NYU Stern School of Business.
Expanding Pipeline Opportunities
McElheny expressed enthusiasm about joining Humacyte during this pivotal period, highlighting the company's diverse pipeline opportunities. "Our broad pipeline, including Symvess (搜索)® and our earlier-stage programs in coronary bypass graft surgery and the BioVascular Pancreas for Type 1 diabetes (搜索), create multiple collaboration opportunities," he said.
Commercial-Stage Platform
Humacyte develops universally implantable, bioengineered human tissues at commercial scale. The company's Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma (搜索) indication received FDA approval in December 2024. ATEVs are currently in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease (搜索).
The company's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Additionally, Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma (搜索) and for advanced PAD have both received RMAT designations.
Future Development Programs
Preclinical development is underway for coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes (搜索), and multiple novel cell and tissue applications. The ATEV has also received priority designation for the treatment of vascular trauma (搜索) by the U.S. Secretary of Defense.
McElheny's role will focus on driving strategic partnerships to accelerate the availability of these innovative products to patients worldwide, as Humacyte continues to expand the reach of its groundbreaking bioengineered tissues.